BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.14
+0.42 (+0.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close102.72
Open103.22
Bid0.00 x 800
Ask0.00 x 3100
Day's Range102.44 - 103.71
52 Week Range75.81 - 106.20
Volume560,305
Avg. Volume1,289,009
Market Cap18.317B
Beta2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est119.35
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    3 Biotech Stock Favorites to Bet on Today: Top Analysts

    To trade momentum biotech stocks, it's often best to follow the top experts. Using TipRanks' Top-Rated Stocks investor tool, we can see which biotech names float as Wall Street's most recommended stocks today.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist5 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals
    Market Realist6 days ago

    Wall Street Analysts Are Mostly Positive on Jazz Pharmaceuticals

    In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.

  • Investor's Business Daily7 days ago

    Why Spark Therapeutics' Crash On Hemophilia A Led This Rival To Pop

    Spark Therapeutics crashed Tuesday after its hemophilia A study results seemingly lagged a rival treatment from BioMarin Pharmaceutical. Spark plunged 27.8% in high volume.

  • Backed with $140M, startup launches three-pronged attack on liver diseases
    American City Business Journals6 days ago

    Backed with $140M, startup launches three-pronged attack on liver diseases

    Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.

  • How Did Jazz Pharmaceuticals Perform in the Second Quarter?
    Market Realist6 days ago

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

  • How Ionis’s Q2 2018 Earnings Trended
    Market Realist7 days ago

    How Ionis’s Q2 2018 Earnings Trended

    Ionis Pharmaceuticals (IONS), one of the leading biopharmaceutical companies, is focused on developing RNA-targeted therapies. Ionis has developed many drugs for the treatment of various life-threatening diseases through its broadly applicable drug discovery platform. Ionis missed Wall Street analyst estimates and reported earnings per share of -$0.29 on revenues of $117.7 million during Q2 2018 as compared to EPS estimates of -$0.09 on revenues of $135.5 million during the quarter.

  • Zacks7 days ago

    NASDAQ, S&P Within 1% of New Highs

    NASDAQ, S&P Within 1% of New Highs

  • BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%
    Zacks7 days ago

    BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%

    BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Benzinga7 days ago

    The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding BMRN is favorable, with net inflows of $17.81 billion.

  • Investopedia7 days ago

    Despite Recent Volatility, Biotech Stocks Look Poised to Pop

    Biotechnology investors are no strangers to volatility, and Tuesday's price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday's trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial.

  • Barrons.com7 days ago

    8 Biotechs Still Worth Buying After a Sector Surge

    Stifel updated its outlook on the biotech sector, and sees reason to be bullish on several big names. While biotech has had its ups and downs, in general this has been a good year to be in the sector: The iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) have risen 10.7% and 12.8%, respectively, since the start of 2018, above the broader market and even the gain seen by the increasing popular health-care sector itself, as the Health Care Select Sector SPDR ETF (XLV) is up 8.8% since the start of the year.  While smaller biotechs have benefited more from the moves, there are still some bigger companies that warrant attention, argues Stifel's Paul Matteis. Stifel transferred and initiated coverage on a number of biotech stocks, today, with Buy ratings on Vertex Pharmaceuticals  (VRTX), BioMarin Pharmaceuticals (BMRN), Biogen (BIIB), Alnylam Pharmaceuticals (ANLY), Sage Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Wave Life Sciences (WVE), and Alder BioPharmaceuticals (ALDR).

  • BioMarin Pharmaceutical Sets Its Sights on $2 Billion
    Motley Fool7 days ago

    BioMarin Pharmaceutical Sets Its Sights on $2 Billion

    Management thinks it can get there with its latest drug approval.

  • Estimates and Recommendations for BeiGene on August 7
    Market Realist7 days ago

    Estimates and Recommendations for BeiGene on August 7

    BeiGene (BGNE) reported revenues of $32.5 million and EPS of -$2.03 in the first quarter. Analysts expect BeiGene to report EPS of -$2.06 on revenues of $22.5 million during the second quarter. This represents 100.0% growth in its YoY (year-over-year) revenues, compared to zero revenues during the second quarter of 2017. The chart below compares analysts’ recommendations over the last 12 months.

  • MarketWatch8 days ago

    Spark Therapeutics stock plummets 28% premarket on hemophilia trial's patient safety concerns

    Spark Therapeutics Inc. (ONCE) shares dropped 28% in Tuesday premarket trade after the company said two patients in its hemophilia phase 1/2 trial had a concerning immune response, one of whom was hospitalized as a result. Twelve patient total have been dosed so far in the clinical trial, which is testing the company's gene therapy SPK-9001 in patients with hemophilia B, and the therapy's effect on patients' clotting factor levels was an important outcome.

  • CNBC8 days ago

    Spark Therapeutics shares lose a third of their value as hemophilia gene therapy trial disappoints

    Spark Therapeutics says its experimental treatment for hemophilia A reduced bleeds and the need for therapeutic infusions by 97 percent in a trial of 12 patients. Investors were disappointed by the results and sent the shares plunging by as much as 32 percent before the market opened. Shares of biotechnology company Spark Therapeutics ONCE slid more than 30 percent in premarket trading Tuesday after the company reported the results of a small trial for an experimental gene therapy treatment for hemophilia that reduced bleeds in most patients but sent one to the hospital.

  • Bluebird Bio Misses Analysts’ Estimates in Q2 2018
    Market Realist12 days ago

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.

  • BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat
    Zacks12 days ago

    BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat

    BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of BMRN earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Biomarin Pharmaceutical Inc Earnings Call

  • Investor's Business Daily12 days ago

    BioMarin Dips On Mixed Second Quarter But Sales Outlook In Line

    BioMarin Pharmaceutical reported a mixed second quarter on Thursday, as revenue topped expectations but adjusted income lagged Street estimates. In after-hours trading, BioMarin shares dipped more than 1%.

  • Associated Press12 days ago

    BioMarin: 2Q Earnings Snapshot

    The San Rafael, California-based company said it had a loss of 9 cents per share. Earnings, adjusted for stock option expense and amortization costs, came to 12 cents per share. The results did not meet ...

  • PR Newswire12 days ago

    BioMarin Announces Second Quarter 2018 Results

    - Total Revenues of $372.8 million in the Quarter - Received Approval of its Seventh Commercial Product, Palynziq™ Injection for Treatment of Adults with Phenylketonuria - Provided Two Years of Clinical ...

  • ACCESSWIRE12 days ago

    BioMarin Pharmaceutical Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
    Zacks14 days ago

    Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More

    Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.